VTGN News and Press, VistaGen Therapeutics Inc. From 04/09/24

Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience to deliver groundbreaking therapies for individuals affected by psychiatric and neurological disorders, today announced that it will present posters detailing clinical trial data for fasedienol, an ...

Vistagen (NASDAQ: VTGN) is a late clinical-stage biopharmaceutical company pioneering neuroscience to deliver groundbreaking therapies for individuals affected by psychiatric and neurological disorders. The company today announced that it has enrolled the first patient in its PALISADE-3 Phase 3 ...

Key study underway in registration-directed PALISADE Phase 3 program for fasedienol in social anxiety disorder Social anxiety disorder affects over 25 million Americans Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience to delive...

2024-03-20 21:01:28 ET Summary Vistagen Therapeutics has proprietary platform technologies for developing innovative drugs for mental health disorders. The company's pipeline includes candidates for social anxiety disorder, major depressive disorder, vasomotor symptoms, and more. ...

2024-03-17 03:07:49 ET Summary VistaGen Therapeutics is developing CNS drugs for anxiety, depression, and other disorders, with Fasedienol in phase 3 clinical trials. Fasedienol has advantages as a non-systemic, low-abuse anxiolytic and is seeking Breakthrough Therapy Designation....

Vistagen Therapeutics (NASDAQ: VTGN) , a biopharmaceutical company pioneering neuroscience to deliver groundbreaking therapies for individuals affected by psychiatric and neurological disorders, will be featured at the upcoming Stifel 2024 Virtual CNS Days. The two-day online event is scheduled f...

Vistagen (Nasdaq: VTGN), a biopharmaceutical company pioneering neuroscience to deliver groundbreaking therapies for individuals affected by psychiatric and neurological disorders, today announced that company management will present and host one-on-one meetings during the Stifel 2024 Virtual CNS...

Vistagen (NASDAQ: VTGN) , a biopharmaceutical company pioneering neuroscience to deliver groundbreaking therapies for individuals affected by psychiatric and neurological disorders, today announced that company management will present and host one-on-one meetings at the TD Cowen 44th Annual Healt...

Vistagen (Nasdaq: VTGN), a biopharmaceutical company pioneering neuroscience to deliver groundbreaking therapies for individuals affected by psychiatric and neurological disorders, today announced that company management will present and host one-on-one meetings at the TD Cowen 44 th Annual H...

2024-02-19 12:24:46 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Investing in high-potential biotech stocks should catapult your portfolio to new heights. Picture this: a global biotech market valued at a whopping $1.55 trillion in 2023 is set to catapul...